Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease

Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease

Submitted by admin on November 3, 2020 - 10:54am
Source: 
Pharmaceutical Business Review
News Tags: 
Neuraly
NLY01
clinical trials
Alzheimer's disease
Headline: 
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease
snippet: 

Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease.

Do Not Allow Advertisers to Use My Personal information